Humanized antibodies against CD269 (BCMA)

US10851172B2 · kind B2 · utility

Assignee

• Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft · DE

Inventors

• Felix Oden · Berlin, DE
• Stephen Marino · Berlin, DE
• Oliver Daumke · Berlin, DE

Key dates

• Filing date: Oct 25, 2018
• Grant date: Dec 1, 2020
• Expiry date: Oct 25, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA).